Causes of death and mortality in hypertrophic cardiomyopathy patients with implantable defibrillators in Sweden

被引:7
作者
Magnusson, Peter [1 ,2 ]
Gadler, Fredrik [1 ]
Liv, Per [2 ]
Morner, Stellan [3 ,4 ]
机构
[1] Karolinska Inst, Cardiol Res Unit, Dept Med, Stockholm, Sweden
[2] Uppsala Univ Reg Gavleborg, Ctr Res & Dev, Gavle, Sweden
[3] Umea Univ, Ctr Heart, Umea, Sweden
[4] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden
关键词
epidemiology; heart failure; hypertrophic cardiomyopathy; implantable defibrillator; mortality; SUDDEN CARDIAC DEATH; CARDIOVERTER-DEFIBRILLATORS; RISK STRATIFICATION; CLINICAL PROFILE; HEART-FAILURE; PREVALENCE; PREVENTION; VALIDATION; CARDIOLOGY; SOCIETY;
D O I
10.2459/JCM.0000000000000359
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsImplantable defibrillators (ICDs) successfully terminate ventricular arrhythmias in hypertrophic cardiomyopathy (HCM), protect against bradycardia, and monitor atrial arrhythmias. This may alter the natural history and causes of death.MethodsThis nationwide observational longitudinal retrospective study of all HCM patients implanted during 1995-2012 obtained data from the Swedish ICD Registry, the National Patient Register, the Cause of Death Register, and were validated by review of medical records.ResultsOf 342 patients (mean age 51.8 years, 70.8% males), 45 died during a total follow-up of 1847 years (mean 5.4 years). Mean age at death was 68.2 years (range 21-83 years; 12 were 75 years). Mean follow-up time among the deceased was 4.9 years (quartiles 1.4-7.4 years). All-cause mortality was higher in HCM patients compared with the age and sex-matched Swedish general population (standardized mortality ratio 3.4; 95% confidence interval 2.4-4.5; P<0.001). Main cause of death was heart failure (n=27), stroke (n=5), cancer (n=3), myocardial infarction (n=2), sepsis (n=2), and others (n=4). Two patients died suddenly, one after the ICD was turned off because of inappropriate shocks, and one patient whose device system was removed after infection. HCM was the main cause of death in 76% of the cases, mainly because of progressive heart failure.ConclusionFor HCM patients, ICDs almost eliminate premature arrhythmic death and result in a shift to heart failure as the cause of death in the majority of cases. Still, mortality in HCM patients remains elevated and management of heart failure and comorbidities must be improved to increase survival.
引用
收藏
页码:478 / 484
页数:7
相关论文
共 24 条
  • [1] Dilated-hypokinetic evolution of hypertrophic cardiomyopathy - Prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients
    Biagini, E
    Coccolo, F
    Ferlito, M
    Perugini, E
    Rocchi, G
    Bacchi-Reggiani, L
    Lofiego, C
    Boriani, G
    Prandstraller, D
    Picchio, FM
    Branzi, A
    Rapezzi, C
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (08) : 1543 - 1550
  • [2] 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)
    Elliott, Perry M.
    Anastasakis, Aris
    Borger, Michael A.
    Borggrefe, Martin
    Cecchi, Franco
    Charron, Philippe
    Hagege, Albert Alain
    Lafont, Antoine
    Limongelli, Giuseppe
    Mahrholdt, Heiko
    McKenna, William J.
    Mogensen, Jens
    Nihoyannopoulos, Petros
    Nistri, Stefano
    Pieper, Petronella G.
    Pieske, Burkert
    Rapezzi, Claudio
    Rutten, Frans H.
    Tillmanns, Christoph
    Watkins, Hugh
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 (39) : 2733 - +
  • [3] Current use of implantable electrical devices in Sweden: data from the Swedish pacemaker and implantable cardioverter-defibrillator registry
    Gadler, Fredrik
    Valzania, Cinzia
    Linde, Cecilia
    [J]. EUROPACE, 2015, 17 (01): : 69 - 77
  • [4] 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
    Gersh, Bernard J.
    Maron, Barry J.
    Bonow, Robert O.
    Dearani, Joseph A.
    Fifer, Michael A.
    Link, Mark S.
    Naidu, Srihari S.
    Nishimura, Rick A.
    Ommen, Steve R.
    Rakowski, Harry
    Seidman, Christine E.
    Towbin, Jeffrey A.
    Udelson, James E.
    Yancy, Clyde W.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (25) : E212 - E260
  • [5] Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA)
    Guttmann, Oliver P.
    Pavlou, Menelaos
    O'Mahony, Constantinos
    Monserrat, Lorenzo
    Anastasakis, Aristides
    Rapezzi, Claudio
    Biagini, Elena
    Gimeno, Juan Ramon
    Limongelli, Giuseppe
    Garcia-Pavia, Pablo
    McKenna, William J.
    Omar, Rumana Z.
    Elliott, Perry M.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 (08) : 837 - 845
  • [6] Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy
    Harris, Kevin M.
    Spirito, Paolo
    Maron, Martin S.
    Zenovich, Andrey G.
    Formisano, Francesco
    Lesser, John R.
    Mackey-Bojack, Shannon
    Manning, Warren J.
    Udelson, James E.
    Maron, Barry J.
    [J]. CIRCULATION, 2006, 114 (03) : 216 - 225
  • [7] External review and validation of the Swedish national inpatient register
    Ludvigsson, Jonas F.
    Andersson, Eva
    Ekbom, Anders
    Feychting, Maria
    Kim, Jeong-Lim
    Reuterwall, Christina
    Heurgren, Mona
    Olausson, Petra Otterblad
    [J]. BMC PUBLIC HEALTH, 2011, 11
  • [8] Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy
    Maron, Barry J.
    Spirito, Paolo
    Shen, Win-Kuang
    Haas, Tammy S.
    Formisano, Francesco
    Link, Mark S.
    Epstein, Andrew E.
    Almquist, Adrian K.
    Daubert, James P.
    Lawrenz, Thorsten
    Boriani, Giuseppe
    Estes, N. A. Mark, III
    Favale, Stefano
    Piccininno, Marco
    Winters, Stephen L.
    Santini, Massimo
    Betocchi, Sandro
    Arribas, Fernando
    Sherrid, Mark V.
    Buja, Gianfranco
    Semsarian, Christopher
    Bruzzi, Paolo
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (04): : 405 - 412
  • [9] Risk Stratification and Outcome of Patients With Hypertrophic Cardiomyopathy ≥60 Years of Age
    Maron, Barry J.
    Rowin, Ethan J.
    Casey, Susan A.
    Haas, Tammy S.
    Chan, Raymond H. M.
    Udelson, James E.
    Garberich, Ross F.
    Lesser, John R.
    Appelbaum, Evan
    Manning, Warren J.
    Maron, Martin S.
    [J]. CIRCULATION, 2013, 127 (05) : 585 - 593
  • [10] Hypertrophic cardiomyopathy
    Maron, Barry J.
    Maron, Martin S.
    [J]. LANCET, 2013, 381 (9862) : 242 - 255